Securities code: 300436 securities abbreviation: Fujian Cosunter Pharmaceutical Co.Ltd(300436) Announcement No.: 2022015 Fujian Cosunter Pharmaceutical Co.Ltd(300436)
Announcement on the resolution of the 10th meeting of the 4th board of supervisors
The company and all members of the board of supervisors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Meetings of the board of supervisors
The 10th meeting of the 4th board of supervisors of Fujian Cosunter Pharmaceutical Co.Ltd(300436) (hereinafter referred to as “the company”) was notified by e-mail on February 12, 2022 and held in the conference room on the third floor of the company, block B, building 10, software park, No. 89, software Avenue, Gulou District, Fuzhou, Fujian Province on February 16, 2022. The meeting was presided over by the chairman of the board of supervisors. Three supervisors should be present at the meeting, three actually present, and all three supervisors participated in the voting. The meeting was held in accordance with the provisions of the company law and the articles of association.
2、 Deliberation at the meeting of the board of supervisors
1. The proposal on changing the subject of the commitment of some senior managers to increase their shareholding in the company was reviewed and passed. After review, the board of supervisors believed that the change of commitment was in line with the actual situation and conducive to ensuring the substantive performance of the commitment, Comply with the provisions of laws, regulations and normative documents such as the guidelines for the supervision of listed companies No. 4 – commitments of listed companies and their related parties of the CSRC, and there is no situation that damages the interests of the company and all shareholders. The board of supervisors agrees to change the commitments and agrees to submit them to the general meeting of shareholders for deliberation.
For details, the company disclosed on cninfo.com on the same day（ http://www.cn.info.com.cn. ）Announcement on changing the commitment subject of some senior managers to increase their shareholding in the company (Announcement No.: 2022016).
The proposal was considered and adopted by 3 votes in favor, 0 against and 0 abstention. This proposal must be submitted to the general meeting of shareholders for deliberation.
2. The proposal on the transfer of development expenditure to expense and the provision for asset impairment was reviewed and approved
After review, the board of supervisors believes that the transfer of R & D project development expenditure to expense and the provision for asset impairment of the company comply with the relevant provisions of the accounting standards for business enterprises and the actual situation of the company, can more objectively, fairly and truly reflect the financial status and asset value of the company, and there is no situation that damages the interests of the company and all shareholders, especially small and medium-sized shareholders, Agree to the company’s current provision for asset impairment.
For details, the company disclosed on cninfo.com on the same day（ http://www.cn.info.com.cn. ）Announcement on recognition of transfer of development expenditure to expense and provision for asset impairment (Announcement No.: 2022017). The proposal was considered and adopted by 3 votes in favor, 0 against and 0 abstention.
3、 Documents for future reference
1. Resolutions of the 10th meeting of the 4th board of supervisors;
2. Other documents required by Shenzhen Stock Exchange.
It is hereby announced.
Fujian Cosunter Pharmaceutical Co.Ltd(300436) board of supervisors
February 16, 2022
